331 related articles for article (PubMed ID: 24517491)
21. Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Page CP
Int Arch Allergy Immunol; 2014; 165(3):152-64. PubMed ID: 25532037
[TBL] [Abstract][Full Text] [Related]
22. Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS.
Bodkhe S; Nikam M; Sherje AP; Khan T; Suvarna V; Patel K
Int Immunopharmacol; 2020 Nov; 88():106906. PubMed ID: 33182057
[TBL] [Abstract][Full Text] [Related]
23. Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages.
Milara J; Navarro A; Almudéver P; Lluch J; Morcillo EJ; Cortijo J
Clin Exp Allergy; 2011 Apr; 41(4):535-46. PubMed ID: 21395877
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
Dastidar SG; Rajagopal D; Ray A
Curr Opin Investig Drugs; 2007 May; 8(5):364-72. PubMed ID: 17520865
[TBL] [Abstract][Full Text] [Related]
25. TAS-203, an oral phosphodiesterase 4 inhibitor, exerts anti-inflammatory activities in a rat airway inflammation model.
Demizu S; Asaka N; Kawahara H; Sasaki E
Eur J Pharmacol; 2019 Apr; 849():22-29. PubMed ID: 30716315
[TBL] [Abstract][Full Text] [Related]
26. Roflumilast for the treatment of chronic obstructive pulmonary disease.
Antoniu SA
Curr Opin Investig Drugs; 2006 May; 7(5):412-7. PubMed ID: 16729716
[TBL] [Abstract][Full Text] [Related]
27. Effects of the new benzimidazole derivative TAS-203, an orally active phosphodiesterase 4 inhibitor, on airway inflammation in rats and emetic responses in ferrets.
Asaka N; Kakuo H; Ohmori K; Sasaki E; Togawa M; Yamada S; Oka T; Kiniwa M
Arzneimittelforschung; 2010; 60(9):564-70. PubMed ID: 21117500
[TBL] [Abstract][Full Text] [Related]
28. Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review.
Martin C; Burgel PR; Roche N
Int J Chron Obstruct Pulmon Dis; 2021; 16():2363-2373. PubMed ID: 34429594
[TBL] [Abstract][Full Text] [Related]
29. PDE4: a novel target in the treatment of chronic obstructive pulmonary disease.
Michalski JM; Golden G; Ikari J; Rennard SI
Clin Pharmacol Ther; 2012 Jan; 91(1):134-42. PubMed ID: 22130119
[TBL] [Abstract][Full Text] [Related]
30. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
[TBL] [Abstract][Full Text] [Related]
31. Design and synthesis of a novel class of PDE4 inhibitors with antioxidant properties as bifunctional agents for the potential treatment of COPD.
Wang Y; Wang H; Yang G; Hao Q; Yang K; Shen H; Wang Y; Wang J
Eur J Med Chem; 2023 Aug; 256():115374. PubMed ID: 37150057
[TBL] [Abstract][Full Text] [Related]
32. Single inhibition of either PDE3 or PDE4 unmasks β2-adrenoceptor-mediated inotropic and lusitropic effects in the left but not right ventricular myocardium of rat.
Soler F; Fernández-Belda F; Pérez-Schindler J; Hernández-Cascales J
Eur J Pharmacol; 2015 Oct; 765():429-36. PubMed ID: 26364538
[TBL] [Abstract][Full Text] [Related]
33. Phosphodiesterase 4 inhibitors delay human eosinophil and neutrophil apoptosis in the absence and presence of salbutamol.
Parkkonen J; Hasala H; Moilanen E; Giembycz MA; Kankaanranta H
Pulm Pharmacol Ther; 2008; 21(3):499-506. PubMed ID: 18282775
[TBL] [Abstract][Full Text] [Related]
34. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization.
Tralau-Stewart CJ; Williamson RA; Nials AT; Gascoigne M; Dawson J; Hart GJ; Angell AD; Solanke YE; Lucas FS; Wiseman J; Ward P; Ranshaw LE; Knowles RG
J Pharmacol Exp Ther; 2011 Apr; 337(1):145-54. PubMed ID: 21205923
[TBL] [Abstract][Full Text] [Related]
35. Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
Smith VB; Spina D
Curr Opin Investig Drugs; 2005 Nov; 6(11):1136-41. PubMed ID: 16312135
[TBL] [Abstract][Full Text] [Related]
36. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
[TBL] [Abstract][Full Text] [Related]
37. Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions.
Parikh N; Chakraborti AK
Curr Med Chem; 2016; 23(2):129-41. PubMed ID: 26572614
[TBL] [Abstract][Full Text] [Related]
38. Distinct patterns of constitutive phosphodiesterase activity in mouse sinoatrial node and atrial myocardium.
Hua R; Adamczyk A; Robbins C; Ray G; Rose RA
PLoS One; 2012; 7(10):e47652. PubMed ID: 23077656
[TBL] [Abstract][Full Text] [Related]
39. [Phosphodiesterase-4 inhibitors: roflumilast].
Izquierdo Alonso JL
Rev Clin Esp; 2011 Mar; 211 Suppl 2():22-30. PubMed ID: 21596170
[TBL] [Abstract][Full Text] [Related]
40. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ
Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]